Cencora, Inc. $COR Shares Bought by Generali Asset Management SPA SGR

Generali Asset Management SPA SGR lifted its stake in shares of Cencora, Inc. (NYSE:COR) by 72.2% during the fourth quarter, Holdings Channel reports. The fund owned 22,003 shares of the company’s stock after purchasing an additional 9,224 shares during the quarter. Generali Asset Management SPA SGR’s holdings in Cencora were worth $7,432,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in COR. Oakworth Capital Inc. acquired a new position in Cencora in the 4th quarter valued at about $26,000. Archer Investment Corp boosted its stake in shares of Cencora by 134.3% during the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after purchasing an additional 47 shares during the last quarter. IAG Wealth Partners LLC purchased a new stake in shares of Cencora during the third quarter worth about $30,000. Cloud Capital Management LLC acquired a new position in shares of Cencora in the third quarter valued at approximately $31,000. Finally, Caitlin John LLC acquired a new position in shares of Cencora in the third quarter valued at approximately $31,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Trading Up 2.2%

Shares of COR stock opened at $261.16 on Friday. The company has a quick ratio of 0.51, a current ratio of 0.95 and a debt-to-equity ratio of 3.40. Cencora, Inc. has a fifty-two week low of $244.82 and a fifty-two week high of $377.54. The firm’s 50 day moving average price is $327.81 and its two-hundred day moving average price is $342.26. The stock has a market cap of $50.80 billion, a price-to-earnings ratio of 20.03, a price-to-earnings-growth ratio of 1.19 and a beta of 0.64.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The business had revenue of $78.36 billion during the quarter, compared to analysts’ expectations of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business’s revenue was up 3.9% on a year-over-year basis. During the same period in the prior year, the business posted $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, analysts anticipate that Cencora, Inc. will post 17.62 EPS for the current year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 1st. Shareholders of record on Friday, May 15th will be paid a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Friday, May 15th. Cencora’s payout ratio is currently 28.85%.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. JPMorgan Chase & Co. raised their target price on shares of Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th. Morgan Stanley set a $342.00 price target on Cencora in a research note on Friday. William Blair began coverage on Cencora in a report on Tuesday, April 28th. They set a “market perform” rating on the stock. UBS Group lifted their price objective on Cencora from $410.00 to $412.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Evercore set a $360.00 target price on Cencora in a research note on Wednesday, April 8th. Twelve research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and a consensus target price of $388.42.

More Cencora News

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Cencora raised FY2026 EPS guidance to $17.65-$17.90 and resumed a $1 billion share repurchase program, signaling management confidence in earnings power and capital returns.
• Positive Sentiment: Several Wall Street firms still maintained bullish ratings after cutting price targets, including Citi and Baird, suggesting analysts continue to see upside despite the selloff.
• Neutral Sentiment: Commentary around the stock emphasizes a “valuation debate” and whether the post-earnings decline was overdone, indicating investors are reassessing expectations rather than reacting to a new operational shock. Cencora NYSE Composite Reset Sparks Valuation Debate
• Neutral Sentiment: Analyst and media coverage is also centered on margin expansion versus growth, reflecting debate over whether Cencora is prioritizing profitability and buybacks over top-line momentum. Is Cencora (COR) Prioritizing Margin Expansion Over Growth With Its Raised EPS Outlook and Buybacks?
• Negative Sentiment: The main bearish driver is the earnings report, which missed EPS estimates and came with sales below analyst expectations, raising concerns about near-term growth momentum. Cencora (NYSE:COR) reports sales below analyst estimates in Q1 CY2026 earnings
• Negative Sentiment: A securities fraud investigation announcement could add overhang and legal-risk concerns, potentially worsening sentiment until more details are known. Securities Fraud Investigation Into Cencora, Inc. (COR) Announced

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.